SynthesisFrontiers in oncology2024

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option.

Haeseong Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.